美国安进地舒单抗注射液是一种什么药物呢

Although giant cell tumor of bone progresses slowly, it is often accompanied by severe bone pain, swelling, loss of mobility, and pathological fractures. Prior to this approval, no drug had been approved for the treatment of giant cell tumor of bone. For patients with resectable giant cell tumors of bone, the primary treatment option is surgery. However, some patients require surgeries such as joint resection and amputation that result in significant postoperative functional impairment. A considerable proportion of patients will relapse after the initial surgery, and the recurrence will become more difficult to treat and may metastasize.

Tumor bone metastasis is a common occurrence in all types of tumors. When cancer cells metastasize to bones, the common symptoms are bone damage and severe pain. Bone metastasis often occurs in the lumbar spine, thoracic spine, femur and other parts. Once bone metastasis in these parts occurs, if it cannot be treated in time or is handled improperly, it will lead to complications, loss of mobility or death.

Desosumab is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Desosumab inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

The effect of denosumab on bone reconstruction can be evaluated by measuring some bone renewal markers, such as the bone resorption marker N-telopeptide, the bone formation marker bone-specific alkaline phosphatase, etc. A phase I clinical study conducted in healthy postmenopausal women showed that a dose-dependent decrease in morning urine NTX levels was observed on day 2 after administration. This decrease lasted for 6 months, with the maximum decrease reaching 84% compared with baseline. This effect is reversible. When serum denosumab levels disappear, NTX levels can be seen to rise again, which reflects the reversibility of its effect on bone reconstruction. As treatment continues, these effects will persist for a new cycle.

As a manufacturing company, Amgen Biopharmaceutical Company (Amgen) of the United States is the world's leading innovative biopharmaceutical R&D and production company and one of the largest biopharmaceutical companies in the world. The company was founded by scientist George B. It was co-founded in 1980 by Dr. Rathmann, Dr. Joseph Rubinfeld and other venture capitalists. It takes "drug innovation" as its core concept and attaches great importance to the accumulation of R&D capabilities. It has achieved major breakthroughs in the fields of human genome, tumor biology, neuroscience, hematology and other fields.

Recommended related hot articles: /newsDetail/91205.html